title: [Serum thyroglobulin and whole-body scanning as markers in the follow-up of differentiated thyroid carcinomas].
abstract: We have compared two "markers" in the follow up of post treatment (surgery and therapeutical use of I-131) differentiated thyroid carcinoma. In 153 patients, thyroglobulin (Tg) serum levels were measured after withdrawal of I-thyroxine therapy, before performing a whole-body scan (WBS) with iodine-131; in 55 of these patients, Tg was measured again after at least 45 days of I-thyroxine treatment. The patients were followed between 3 and 10 years, and there were 2713 matched studies. Our results indicate for both parameters, false positive and negative values; sensitivity (SE) for WBS was 89% and specificity (SP) 83%; Tg presents a SE of 86% and SP of 83%. Matching both parameters, SE was 95% and SP 98%. The causes of false results are discussed. Tg determinations under I-thyroxine treatment do not permit the establishment of absence of illness; 37.7% of patients with demonstrated metastases or relapse showed negative Tg values that reached pathological values after suspension of I-thyroxine treatment; another 41.4% with elevated Tg values under therapy reached these values after suspension of I-thyroxine. Both markers, when utilized at the same time, offer the best possibilities in the follow-up of differentiated thyroid carcinoma, when determinations are carried out after suspension of hormonal treatment.
authors.affiliation: Departamento de Medicina Nuclear, Hospital Alemán, Buenos Aires, Argentina.
authors.forename: O J
authors.initials: OJ
authors.lastname: Degrossi
authors.forename: I B
authors.initials: IB
authors.lastname: Rozados
authors.forename: S
authors.initials: S
authors.lastname: Damilano
authors.forename: E B
authors.initials: EB
authors.lastname: Degrossi
authors.forename: L
authors.initials: L
authors.lastname: de Ganino
authors.forename: M
authors.initials: M
authors.lastname: Pinkas
authors.forename: H
authors.initials: H
authors.lastname: García del Río
authors.forename: D
authors.initials: D
authors.lastname: Artagaveytía
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000000981:diagnostic imaging*; D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D002291:Carcinoma, Papillary / Q000097:blood* / Q000000981:diagnostic imaging*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000175:diagnosis; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity; D013954:Thyroglobulin / Q000097:blood*; D013964:Thyroid Neoplasms / Q000097:blood* / Q000000981:diagnostic imaging*; D013974:Thyroxine / Q000008:administration & dosage
chemical_list: D014408:Biomarkers, Tumor; D007457:Iodine Radioisotopes; D013954:Thyroglobulin; D013974:Thyroxine
vernacular_title: La tiroglobina sérica y el rastreo corporal total como indicadores en el seguimiento del carcinoma diferenciado de tiroides.